501 related articles for article (PubMed ID: 3102658)
1. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
Arafah BM; Rosenzweig JL; Fenstermaker R; Salazar R; McBride CE; Selman W
J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
[TBL] [Abstract][Full Text] [Related]
2. Acromegaly with 'normal' serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery.
Brockmeier SJ; Buchfelder M; Adams EF; Schott W; Fahlbusch R
Horm Metab Res; 1992 Aug; 24(8):392-400. PubMed ID: 1526628
[TBL] [Abstract][Full Text] [Related]
3. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
4. Gamma knife radiosurgery for acromegaly--long-term experience.
Jezková J; Marek J; Hána V; Krsek M; Weiss V; Vladyka V; Lisák R; Vymazal J; Pecen L
Clin Endocrinol (Oxf); 2006 May; 64(5):588-95. PubMed ID: 16649981
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly.
Losa M; Oeckler R; Schopohl J; Müller OA; Alba-Lopez J; von Werder K
J Neurosurg; 1989 Apr; 70(4):561-7. PubMed ID: 2647918
[TBL] [Abstract][Full Text] [Related]
6. Somatomedin-C in active and successfully treated acromegaly.
Knappe G; Hesse V; Jahreis G; Rohde W; Gerl H
Exp Clin Endocrinol; 1988 Mar; 91(1):2-6. PubMed ID: 3371416
[TBL] [Abstract][Full Text] [Related]
7. Somatomedin C/insulin-like growth factor I levels after treatment of acromegaly.
Kao PC; Laws ER; Zimmerman D
Ann Clin Lab Sci; 1992; 22(2):95-9. PubMed ID: 1562170
[TBL] [Abstract][Full Text] [Related]
8. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
Abbassioun K; Amirjamshidi M; Mehrazin A; Khalatbary I; Keynama M; Bokai H; Abdollahi M
Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
[TBL] [Abstract][Full Text] [Related]
9. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
11. Gamma-knife surgery is effective in normalising plasma insulin-like growth factor I in patients with acromegaly.
Gutt B; Wowra B; Alexandrov R; Uhl E; Schaaf L; Stalla GK; Schopohl J
Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):219-24. PubMed ID: 15891958
[TBL] [Abstract][Full Text] [Related]
12. Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
Levitt NS; Ratanjee BD; Abrahamson MJ
Horm Metab Res; 1995 Apr; 27(4):185-8. PubMed ID: 7750902
[TBL] [Abstract][Full Text] [Related]
13. Perioperative plasma active and total ghrelin levels are reduced in acromegaly when compared with in nonfunctioning pituitary tumours even after normalization of serum GH.
Kawamata T; Inui A; Hosoda H; Kangawa K; Hori T
Clin Endocrinol (Oxf); 2007 Jul; 67(1):140-4. PubMed ID: 17466003
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between clinical and endocrinological features following transsphenoidal surgery of acromegaly. With special reference to somatomedin-C level].
Osawa M; Kobayashi S; Takemae T; Nakagawa F
Neurol Med Chir (Tokyo); 1988 Mar; 28(3):254-8. PubMed ID: 2457827
[No Abstract] [Full Text] [Related]
15. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
Minniti G; Jaffrain-Rea ML; Osti M; Esposito V; Santoro A; Solda F; Gargiulo P; Tamburrano G; Enrici RM
Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
[TBL] [Abstract][Full Text] [Related]
16. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
17. Dynamic testing in the diagnosis and follow-up of patients with acromegaly.
Wass JA
J Endocrinol Invest; 2003; 26(7 Suppl):48-53. PubMed ID: 14604066
[TBL] [Abstract][Full Text] [Related]
18. Acromegaly in an infant.
Blumberg DL; Sklar CA; David R; Rothenberg S; Bell J
Pediatrics; 1989 Jun; 83(6):998-1002. PubMed ID: 2657629
[TBL] [Abstract][Full Text] [Related]
19. TRH/GnRH test in acromegaly. Long-term follow-up experience with successfully treated patients.
Brockmeier SJ; Buchfelder M; Fahlbusch R
Horm Metab Res; 1993 May; 25(5):275-7. PubMed ID: 8330864
[TBL] [Abstract][Full Text] [Related]
20. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
